Introduction {#jcmm13433-sec-0001}
============

Prostate cancer is the fourth most common cancer and the second most common cancer in men worldwide [1](#jcmm13433-bib-0001){ref-type="ref"}. Prostate cancer is the third most commonly diagnosed cancer in Europe and has emerged as the most frequent cancer in men, reaching an age‐standardized rate of 96 per 100,000 men in 2012 [2](#jcmm13433-bib-0002){ref-type="ref"}. Incidence has been increasing rapidly over the past two decades in most European countries, particularly in the wealthiest countries in Northern and Western Europe [2](#jcmm13433-bib-0002){ref-type="ref"}, [3](#jcmm13433-bib-0003){ref-type="ref"}. More than 1.1 million new cases of prostate cancer were diagnosed in 2012 worldwide, accounting for approximately 8% of all new cancer cases. The incidence is expected to grow to 1.7 million new cases and 500,000 deaths by 2030 worldwide, mainly due to the growth and ageing of the global population [4](#jcmm13433-bib-0004){ref-type="ref"}.

Incidence of prostate cancer differs between countries, in part due to differences in the prevalence of prostate‐specific antigen (PSA) screening. PSA screening has a much greater effect on incidence than on mortality; hence, there is less variation in mortality rates worldwide (10‐fold) than is observed for incidence (25‐fold). In 2012, the age‐standardized mortality rate in Europe was 19 per 100,000 men, and the mortality rate was almost the same in developed and developing regions of Europe [2](#jcmm13433-bib-0002){ref-type="ref"}, [4](#jcmm13433-bib-0004){ref-type="ref"}. Prostate cancer screening with PSA has been shown to decrease prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer (ERSPC) [5](#jcmm13433-bib-0005){ref-type="ref"}. However, the possibility of negative effects of screening on over‐diagnosis and over‐treatment cannot be ignored [6](#jcmm13433-bib-0006){ref-type="ref"}. Screen‐detected prostate cancer typically runs an indolent course, less than 13% of those diagnosed will succumb to the disease [5](#jcmm13433-bib-0005){ref-type="ref"}. To improve the outcome of screening, it is important to find prognostic biomarkers that can distinguish between indolent and aggressive disease [7](#jcmm13433-bib-0007){ref-type="ref"}. Sequence variants that associate with aggressive PCA could be useful for this purpose.

Genome‐wide association study has been remarkably successful in identifying common sequence variants affecting risk of PCA [8](#jcmm13433-bib-0008){ref-type="ref"}. More than 200 SNPS have been identified at 70 loci, explaining 30% of the familial risk of this disease [9](#jcmm13433-bib-0009){ref-type="ref"}. Most GWAS has been conducted in populations with high rates of PSA screening and includes indolent disease with undetermined clinical significance. Not surprisingly, some of the PCA variants reported have subsequently been shown to associate with PSA levels rather than PCA [10](#jcmm13433-bib-0010){ref-type="ref"}.

In Romania, the estimated age‐standardized incidence of PCA was 37.9 per 100,000 men in 2012, and the estimated age‐standardized mortality rate for PCA was 16.9 per 100,000 men [2](#jcmm13433-bib-0002){ref-type="ref"}. Due to the poor health status of the Romanian population and difficulties in healthcare accessibility [11](#jcmm13433-bib-0011){ref-type="ref"}, PCA might be an underdiagnosed condition. PSA screening is not common in Romania [12](#jcmm13433-bib-0012){ref-type="ref"} and consequently more than 95% of patients have an advanced disease at the time of diagnosis [13](#jcmm13433-bib-0013){ref-type="ref"}. Here, we report the first GWAS on PCA in Romania and profile the known PCA risk variants in this populations of patients with clinically significant disease.

Materials and methods {#jcmm13433-sec-0002}
=====================

Study population {#jcmm13433-sec-0003}
----------------

Subjects included in this study were male patients admitted between 2008 and 2012 to two clinics in Bucharest (Urology Clinic 'Th. Burghele' and General Surgery Clinic 'St. Mary') for various medical conditions. The study consists of 2024 hospital patients; 990 unrelated histopathologically confirmed PCA cases, most of which had abnormal PSA levels, and 1034 controls, consisting of patients admitted for urological and surgical conditions other than cancer. Blood samples were collected for the measurement of biomarkers and genotyping. PSA levels in plasma were measured for all subjects at hospital admission but were not used as an exclusion criteria. All subjects gave written informed consent prior to enrolment and accepted the use of personal and clinical data and biological samples for genetic research. The Bioethical Committee of the Romanian College of Physicians approved the study and the study protocols were approved by the National Ethical Board of the Romanian Medical Doctors Association in Romania. Trained interviewers performed face‐to‐face interviews, using standardized questionnaires, to collect personal data (ethnicity, marital status, education, height and weight), lifestyle data (occupation, smoking, coffee and tea consumption) and medical history (personal and familial). All subjects were of self‐reported European descent. No significant difference was observed between the average age of the cases (66.9) and controls (64.3). No significant differences were observed in other epidemiological features: BMI, smoking or alcohol consumptions (Table [1](#jcmm13433-tbl-0001){ref-type="table-wrap"}).

###### 

Description of the Romanian case‐control population

                    \% cases (*n* = 990)   \% controls (*n* = 1034)
  ----------------- ---------------------- --------------------------
  *Age*                                    
  under 50          0.3                    15.5
  50--60            1                      20.1
  60--70            35.5                   26.8
  70--80            44                     31.2
  80--90            15                     6.1
  Over 90           0.2                    0.1
  *T Staging*                              
  1A                2.3                    --
  1B                1.1                    --
  1C                15.6                   --
  2A                1.7                    --
  2B                1.9                    --
  2C                4.0                    --
  3A                43.8                   --
  3B                6.06                   --
  4                 23.3                   --
  *Gleason Score*                          
  2                 0.2                    --
  3                 0.3                    --
  4                 1                      --
  5                 3.3                    --
  6                 13.2                   --
  7                 45.1                   --
  8                 20.3                   --
  *N Staging*                              
  N0                21.5                   --
  N1                3.2                    --
  Nx                75.3                   --
  *M Staging*                              
  M0                22                     --
  M1                10                     --
  Mx                68                     --
  *PSA levels*                             
  \<4               42                     --
  4.0--9.99         18                     --
  9.99--19.99       12                     --
  19.99--49.99      9.5                    --
  49.99--99.99      6.7                    --
  \>100             9.3                    --
  NA                1.5                    --

                           %cases (*n* = 979)   %controls (*n* = 1030)
  ------------------------ -------------------- ------------------------
  *Alcohol consumptions*                        
  No                       43.4                 45.1
  Yes                      56.6                 54.9

              \% cases (*n* = 975)   \% controls (*n* = 1022)
  ----------- ---------------------- --------------------------
  *Smoking*                          
  No          88.1                   81.9
  Yes         11.9                   19.1

                  \% cases (*n* = 979)   \% controls (*n* = 1023)
  --------------- ---------------------- --------------------------
  *BMI*                                  
  Underweight     1.5                    0.5
  Normal weight   37.5                   31.5
  Overweight      45.6                   47.7
  Obese           15.1                   20.3
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The UICC--TNM staging system was used [14](#jcmm13433-bib-0014){ref-type="ref"}. For the T stage, more than 75 per cent of the cases were graded as T3 or T4. The N and M stages were distributed similarly, and a vast majority were staged as Mx or Nx. For the Gleason score, the majority of cases were graded as Gleason 7 or 8 (45.1% and 20.3%, respectively). A complete description of the clinical characteristics of the cohort is found in Table [1](#jcmm13433-tbl-0001){ref-type="table-wrap"}.

Genotyping and analysis of SNP data {#jcmm13433-sec-0004}
-----------------------------------

DNA was extracted from whole blood at deCODE Genetics (Reykjavik, Iceland) and genotyped using Infinium OmniExpress‐24 bead chips (Illumina). A total of 716,503 SNPs were genotyped for each individual included in the study. The genotype data were filtered using Plink! v1.07 [15](#jcmm13433-bib-0015){ref-type="ref"}. Approximately 10% of the SNPs genotyped were removed using a Hardy--Weinberg equilibrium significance threshold of 5 × 10^−6^ and by excluding markers with a minor allele frequency lower than 1%. Prior to the imputation, each chromosome was phased in a single run using SHAPEIT [16](#jcmm13433-bib-0016){ref-type="ref"}. Markers from Phase 3 October 2014 of the 1000 Genomes [17](#jcmm13433-bib-0017){ref-type="ref"} were imputed into the 2024 chip‐typed individuals using the IMPUTE2 software [18](#jcmm13433-bib-0018){ref-type="ref"} with a posterior probability of 0.9 as a threshold to call genotypes. The set of genotypes were tested for population heterogeneity using principal component analysis in the ADMIXTURE software [19](#jcmm13433-bib-0019){ref-type="ref"}, and the results were consistent with a homogeneous population.

A total of 24,295,558 markers were generated by imputation for each individual in the study. Quality control for the imputation results was performed by removing markers with minor allele frequency less than 1%, call rate of 0.95 and info of 0.8. In total, 8,506,022 markers met the filtering criteria. An association test was performed between the 8.5 million imputed markers and a phenotype represented by positive biopsy for prostate cancer. The association test was calculated using SNPTEST [20](#jcmm13433-bib-0020){ref-type="ref"}, using a single binary variable as a response; all reported *P*‐values are two‐sided.

Selection of SNPs for replication of previous findings {#jcmm13433-sec-0005}
------------------------------------------------------

A systematic literature review of variants associated with prostate cancer from previous GWAS' was completed on 4 October 2016 using the NHGRI catalogue of published genome‐wide association studies [21](#jcmm13433-bib-0021){ref-type="ref"} as a starting point. A search query with 'prostate cancer' as a keyword was performed, and the inclusion criteria for selection were as follows: *P*‐values \<5 × 10^−8^ and a minor allele frequency above 5%. For each study, the following variables were collected: country and ethnicity of the participants, genotyping method, source of controls and source of replication cohort, and number of cases and controls in both discovery and replication study.

A total of 37 articles were originally obtained from the GWAS catalogue based on the keyword search. Twelve of the studies reported results only tangentially related to prostate cancer, while the remaining 25 studies reported associations with prostate cancer risk. After removing duplicate markers, we obtained 173 unique markers. Out of the 173, 58 markers did not report either ORs and corresponding 95% CI or the tested allele. These markers were excluded from the study, resulting in a final set of 115 unique variants used in our replication.

Results {#jcmm13433-sec-0006}
=======

To search for new susceptibility loci for prostate cancer, we tested a total of 8.5 million variants of frequency above 1%. No variants tested in the Romanian GWAS reached genome‐wide significance (*P*‐value lower than 5 × 10^−8^), while 635 markers showed association *P*‐values \<1 × 10^−4^ (Supplementary Table [1](#jcmm13433-sup-0001){ref-type="supplementary-material"}) and 41 markers, at 16 genetic loci, showed association *P*‐values \<1 × 10^−5^. Figure [1](#jcmm13433-fig-0001){ref-type="fig"} shows a Manhattan plot of the results. The 16 markers with the lowest *P*‐values at each locus are shown in Table [2](#jcmm13433-tbl-0002){ref-type="table-wrap"}. We observe no excess signal in the Q‐Q plot when testing all marker (Fig. [2](#jcmm13433-fig-0002){ref-type="fig"}A); the observed *P*‐values (blue line) show a comparable trend to the expected *P*‐values (the red line).

![Manhattan plot of GWAS findings in the Romanian sample. Y‐axis shows --log10 *P*‐values and x‐axis shows chromosomal position.](JCMM-22-1574-g001){#jcmm13433-fig-0001}

###### 

The variants in the Romanian GWAS with lowest *P*‐values for each locus MAF = Minor Allele Frequency

  RS ID         Chromosome   Position    Reference allele   Tested allele   Info   MAF\* (%)   OR     *P*‐value
  ------------- ------------ ----------- ------------------ --------------- ------ ----------- ------ ---------------
  rs55960139    13           95288608    T                  C               0.93   22.3        1.45   1.83 × 10^−7^
  rs146493482   16           8002169     C                  T               0.93   2.4         2.86   8.25 × 10^−7^
  rs17467679    2            16133863    A                  G               1      37.8        0.74   9.48 × 10^−7^
  rs35890542    4            177243229   A                  G               1      6.6         0.54   1.67 × 10^−6^
  rs187936586   11           21614186    T                  C               0.88   2.4         0.38   3.50 × 10^−6^
  rs13111983    4            710801      T                  G               0.91   27.1        0.74   4.08 × 10^−6^
  rs1383        14           73129765    T                  A               0.83   23.4        1.36   4.18 × 10^−6^
  rs6834053     4            127918594   C                  A               0.93   3.9         2.14   4.70 × 10^−6^
  rs35544574    13           37172379    CAA                C               0.95   9.2         1.6    4.72 × 10^−6^
  rs74437803    22           17089228    G                  A               0.81   8.4         0.63   5.60 × 10^−6^
  rs71751677    16           11314438    GTGTTT             G               0.86   48.7        0.78   6.16 × 10^−6^
  rs201872456   2            115129517   C                  G               0.8    17.3        1.38   6.59 × 10^−6^
  rs183478269   1            161032417   G                  C               0.82   1.5         3.08   6.97 × 10^−6^
  rs13253942    8            126154649   G                  A               1      9.5         1.63   7.93 × 10^−6^
  rs148921321   8            76468497    C                  T               0.93   2.1         0,31   8.67 × 10^−6^
  rs133917      22           44524314    C                  T               0.81   47.3        1.27   8.89 × 10^−6^
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![Q‐Q plot of the association results. Blue dots show observed *P*‐values, and red line shows expected *P*‐values. (**A**) Shows results from genome‐wide analysis; (**B**) Shows results when restricted to GWAS catalogue markers.](JCMM-22-1574-g002){#jcmm13433-fig-0002}

Next, we tested the effect of 115 previously reported PCA variants in the Romanian population. Thirty SNPs from 13 loci replicated in the Romanian cohort (*P*‐value \<0.05) (Table [3](#jcmm13433-tbl-0003){ref-type="table-wrap"}). Eighty‐nine (77%) of the markers selected in the systematic literature review show effects consistent with reported studies although the *P* values were not \<0.05. We observe an excess of signal in the Q‐Q plot when restricted to this set of previously reported variants (Fig. [2](#jcmm13433-fig-0002){ref-type="fig"}B); the observed *P*‐values (blue line) show a steeper slope than the expected *P*‐values (the red line).

###### 

Previously reported PCa risk markers that associated with PCa risk in the Romanian population with *P* value \< 0.05

  Rs Number    Chr   Position    OR (95% CI)         *P*‐value    Tested allele   Mapped gene      eQTL genes
  ------------ ----- ----------- ------------------- ------------ --------------- ---------------- -----------------------------------------------
  rs636291     1     10496040    1.19 (1.05, 1.35)   8 × 10^−3^   A               PEX14            PEX14, PGD, APITD1
  rs1218582    1     154861707   1.13 (1.01, 1.26)   4 × 10^−2^   G               KCNN3            KCNN3, PBXIP1
  rs7611694    3     113556777   1.14 (1.01, 1.29)   3 × 10^−2^   A               SIDT1            SIDT1, WDR52
  rs7679673    4     105140377   1.15 (1.02, 1.29)   2 × 10^−2^   C               TET2             PPA2
  rs2242652    5     1279913     1.23 (1.06, 1.42)   5 × 10^−3^   C               TERT             --
  rs7725218    5     1282299     1.21 (1.09, 1.36)   7 × 10^−4^   G               TERT             CTD‐2228K2.7
  rs9364554    6     160412632   1.28 (1.11, 1.47)   4 × 10^−4^   T               SLC22A3          SLC22A3
  rs7758229    6     160419220   1.23 (1.08, 1.40)   1 × 10^−3^   T               SLC22A3          SLC22A3
  rs1016343    8     127081052   1.30 (1.13, 1.50)   2 × 10^−4^   T               PCAT2, PRNCR1    --
  rs13254738   8     127092098   1.13 (1.01, 1.28)   4 × 10^−2^   C               PCAT2, PRNCR2    --
  rs12682344   8     127094539   1.58 (1.13, 2.20)   7 × 10^−3^   G               PCAT2, PRNCR3    --
  rs6983561    8     127094635   1.58 (1.13, 2.21)   7 × 10^−3^   C               PCAT2, PRNCR4    --
  rs16901979   8     127112671   1.58 (1.13, 2.21)   7 × 10^−3^   A               PCAT2, PRNCR5    --
  rs10505483   8     127112950   1.58 (1.13, 2.21)   7 × 10^−3^   T               PCAT2, PRNCR6    --
  rs445114     8     127310936   1.23 (1.09, 1.39)   1 × 10^−3^   T               PCAT2, PRNCR7    --
  rs6983267    8     127401060   1.16 (1.03, 1.31)   1 × 10^−2^   G               PCAT2, PRNCR8    CASC8
  rs1447295    8     127472793   1.35 (1.11, 1.64)   3 × 10^−3^   A               PCAT2, PRNCR9    --
  rs4242382    8     127505328   1.33 (1.10, 1.62)   3 × 10^−3^   A               PCAT2, PRNCR10   --
  rs4242384    8     127506309   1.33 (1.10, 1.62)   3 × 10^−3^   T               PCAT2, PRNCR11   --
  rs10090154   8     127519892   1.32 (1.09, 1.60)   4 × 10^−3^   T               PCAT2, PRNCR12   --
  rs11228565   11    69211113    1.19 (1.03, 1.38)   2 × 10^−2^   A               MMP7, MMP20      --
  rs7929962    11    69218116    1.25 (1.11, 1.40)   3 × 10^−4^   T               MMP7, MMP20      RP11‐554A11.9
  rs7931342    11    69227030    1.23 (1.09, 1.39)   6 × 10^−4^   G               MMP7, MMP20      RP11‐554A11.9
  rs10896449   11    69227200    1.24 (1.10, 1.40)   3 × 10^−4^   G               MMP7, MMP20      RP11‐554A11.9
  rs11568818   11    102530930   1.19 (1.05, 1.34)   5 × 10^−3^   A               MMP7, MMP20      MMP7
  rs10875943   12    49282227    1.16 (1.02, 1.32)   3 × 10^−2^   C               TUBA1C           FKBP11, LMBR1L, TUBA1C, C1QL4, RP11‐386G11.10
  rs4430796    17    37738049    1.16 (1.03, 1.31)   2 × 10^−2^   A               HNF1B            --
  rs8064454    17    37741595    1.20 (1.06, 1.35)   3 × 10^−3^   C               HNF1B            --
  rs2735839    19    50861367    1.20 (1.01, 1.42)   3 × 10^−2^   G               KLK3             --
  rs5759167    22    43104206    1.21 (1.08, 1.36)   1 × 10^−3^   G               BIK              --
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Replication, or lack thereof, allows us to refine association signals and rule out associations due to differences in phenotype definitions between cohorts. Compared to the original studies, replication studies may use cohorts with slightly different ethnic and pathologic characteristic. Differences in ethnic characteristics lead to differences in LD structure and consequently markers that were previously found to be correlated with a risk variant may not show an association in a population of different ethnicity. We determined whether the effects of the 115 reported SNPs are similar in the Romanian population as in the discovery cohorts, by conducting a weighted linear regression, modelling the relationship between the log‐odds ratio of each of the 115 SNP (Fig. [3](#jcmm13433-fig-0003){ref-type="fig"}). We observed a highly significant correlation of *R* = 0.66 (*P*‐value = 5 × 10^−16^) for the 115 markers represented by the grey (non‐replicating) and orange (replicating) dots. Most markers are near the diagonal, indicating that the effect in the Romanian population is similar to that previously reported.

![Scatter plot showing the association of the 115 previously reported SNPs with PCA \[log(OR)\] in the Romanian data set (*x*‐axis) and in reported articles (*y*‐axis).](JCMM-22-1574-g003){#jcmm13433-fig-0003}

The locus showing the strongest replication in the Romanian GWAS is 8q24 represented by 12 variants with *P*‐values ranging from 2 × 10^−4^ to 4 × 10^−2^. These 12 SNPs are in high LD (average *R* ^2^ = 0.81) clustering in a 500 kb region, all representing the same association signal. The closest gene to this locus is the *MYC* gene. The locus showing the second strongest replication in Romania is 11q13.3 located close to the *MYEVO* gene [20](#jcmm13433-bib-0020){ref-type="ref"}. This locus is represented by 4 SNPs with *P*‐values between 2.7 × 10^−4^ and 2.1 × 10^−2^. All four SNPs are in high LD (R^2^ \>0.93) clustering in a 10KB region and represent the same association signal. This locus was previously reported to associate with early‐onset PCA [22](#jcmm13433-bib-0022){ref-type="ref"}. We assessed the association with early‐onset PCA in the Romanian cohort using the same criteria as in the original study, but could not replicate this result (*P* = 0.41, OR = 0.81), possibly due to lack of power in our set of 128 early‐onset PCA cases. The locus showing the third strongest replicated association in the Romanian results is 6q25.3, represented by a pair of markers (rs7758229 *P* = 1.5 × 10^−3^ and rs9364554 *P* = 4.7 × 10^−4^) in strong LD (*R* ^2^ \> 0.78). The markers are located in the proximity of *SLC22A3*, a gene that has been implicated in prostate cancer pathogenesis [23](#jcmm13433-bib-0023){ref-type="ref"}. The 17q12 locus was replicated by a pair of markers in high LD (rs8064454 *P* = 3.1 × 10^−3^ and rs4430796 *P* = 1.5 × 10^−2^, *R* ^2^ \> 0.96) clustering in a 5KB region next to the *HNF1B* gene, representing the same association signal.

Discussion {#jcmm13433-sec-0007}
==========

Genetic epidemiology straddles between statistically driven research and research inspired by clinical needs. Genome‐wide association studies have successfully yielded loci associated with PCA risk; however, none of the variants at these loci conclusively separate aggressive from indolent disease. Most previous GWAS' investigating PCA are based on cohorts including indolent cancer forms, including cases with low stage and grade. In an attempt to search for loci of clinical importance, the present study focused on refining associations in men with clinical presentations and not those identified solely by an elevated PSA. More than 70% of the cases included in our study presented with a Gleason score equal to or greater than 7, and a majority were staged at T3 and T4. This is a clear indication of aggressiveness of the tumours; therefore, the replicated variants are likely to represent associations with clinically significant disease although they may also associate with the indolent form of the disease.

At least two studies of similar size have been performed including clinically advanced cases [24](#jcmm13433-bib-0024){ref-type="ref"}, [25](#jcmm13433-bib-0025){ref-type="ref"}. In both studies, the patients had less advanced clinical characteristics than the Romanian cohort. In both studies, fewer than 50% of cases presented with stage T3 and T4 or Gleason score equal to or higher than 7 [24](#jcmm13433-bib-0024){ref-type="ref"}, [26](#jcmm13433-bib-0026){ref-type="ref"}. Despite the clinically well‐defined population, no variants tested in the Romanian GWAS reached genome‐wide significance (*P*‐value lower than 5 × 10^−8^). The GWAS Q‐Q plot (Fig. [2](#jcmm13433-fig-0002){ref-type="fig"}A) and the lack of novel genome‐wide significant results suggest that our data set is under‐powered to detect genome‐wide significant associations on its own.

Although only 30 of the 115 previously reported markers showed *P*‐values \< 0.05, the effects of additional 59 markers were consistent with the reported results. The 'winner\'s curse', the observation that effect sizes are often larger in the populations in which they are discovered, may be one reason why some SNPs failed to replicate, and why ORs were generally smaller in our cohort than previously found [27](#jcmm13433-bib-0027){ref-type="ref"}. Previous studies have shown the utility of including functional evaluation, in an attempt to identify candidate risk loci below currently accepted statistical levels of genome‐wide significance [28](#jcmm13433-bib-0028){ref-type="ref"}. Functional characterization of the variants described here remains to be done. However, the GTEx database [29](#jcmm13433-bib-0029){ref-type="ref"} suggests that some of the markers may influence gene expression.

It is interesting to note that many of the variants showing the strongest replication in the Romanian population reside at loci that have been associated with several cancer types, so‐called cancer hubs. The locus showing the strongest replication *P*‐value (2 × 10^−4^) in the Romanian GWAS is 8q24, one of the first hotspots for cancer risk alleles reported. In addition to PCA, the locus was previously reported to associate with breast cancer [30](#jcmm13433-bib-0030){ref-type="ref"}, colorectal cancer [31](#jcmm13433-bib-0031){ref-type="ref"}, [32](#jcmm13433-bib-0032){ref-type="ref"}, ovarian cancer [33](#jcmm13433-bib-0033){ref-type="ref"}, pancreatic cancer [34](#jcmm13433-bib-0034){ref-type="ref"}, renal cell carcinoma [35](#jcmm13433-bib-0035){ref-type="ref"}, urinary bladder cancer [36](#jcmm13433-bib-0036){ref-type="ref"} and Hodgkin\'s lymphoma [37](#jcmm13433-bib-0037){ref-type="ref"}. The closest genes to this locus is the *MYC* gene.

A similar situation is found in the case of 11q13.3, a locus associated with breast cancer [38](#jcmm13433-bib-0038){ref-type="ref"}, [39](#jcmm13433-bib-0039){ref-type="ref"} and early‐onset breast cancer [40](#jcmm13433-bib-0040){ref-type="ref"}, renal cell carcinoma [41](#jcmm13433-bib-0041){ref-type="ref"} and multiple myeloma [42](#jcmm13433-bib-0042){ref-type="ref"}, in addition to PCA [43](#jcmm13433-bib-0043){ref-type="ref"}, [44](#jcmm13433-bib-0044){ref-type="ref"} and early‐onset PCA [22](#jcmm13433-bib-0022){ref-type="ref"}.

Yet, another locus replicating in our study that is associated with several types of cancer is the *TERT* locus at 5p15.33. Variants at this locus have been associated with risk of lung cancer [45](#jcmm13433-bib-0045){ref-type="ref"}, pancreatic cancer [46](#jcmm13433-bib-0046){ref-type="ref"}, breast cancer [47](#jcmm13433-bib-0047){ref-type="ref"}, testicular cancer [48](#jcmm13433-bib-0048){ref-type="ref"} and bladder cancer [49](#jcmm13433-bib-0049){ref-type="ref"}. The two markers replicated in this region, rs2242652 and rs7725218, are both located in the intron region of the *TERT* gene, a gene known to be involved in the activation of oncogenic pathways.

Our study provides evidence that a large fraction of previously validated prostate cancer SNPs associate with risk in the unscreened Romanian population. These variants are likely to have clinical importance and can be considered for inclusion in future risk models of potential clinical utility.
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